Mixed findings on oncology drugs . . . and other stories
BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j202 (Published 19 January 2017) Cite this as: BMJ 2017;356:j202
Oncology drugs and overall survival
An analysis of 53 new cancer drugs licensed between 2003 and 2013 tried to determine their added value using health technology assessments in England, France, and Australia (JAMA Oncol doi:10.1001/jamaoncol.2016.4166). The studies showed a wide range in the size of effects, which made them hard to assess owing to a mix of comparators and varying outcome measures. About 40% of the drugs improved quality of life, and about the same quantity reduced patient safety. The mean increase in overall survival over this period was 3.4 months.
Palliative care and overall survival
Few cancer trials compare active treatment with palliative care alone for those with advanced disease. Systematic reviewers found 10 trials between 1977 and 2009 that met their inclusion …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.